Company: BIAF
Filing Date: 2025-09-30
Form Type: 424B4
Source: 0001493152-25-016338
Chunk: 40

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-30
Form: 424B4
Chunk 40
---
 reservation and listing of Common 
 Stock, and no subsequent equity sales for 30 days.                                                                                   |

Delivery of the shares of Common Stock and Pre-Funded Warrants offered hereby is expected to occur on or about September 30, 2025, subject to satisfaction of certain customary closing conditions.

Fees and Expenses

The following table shows the per share price and total cash fees we will pay to the Placement Agent in connection with the sale of the securities pursuant to this prospectus.

|                                |     | Per   
 Share |      |     | Per Pre-Funded Warrant |       |     | Total |              |
|:-------------------------------|:----|:------|-----:|:----|:-----------------------|------:|:----|:------|-------------:|
| Public offering price          |     | $     | 2.50 |     | $                      | 2.493 |     | $     | 4,798,284.03 |
| Placement Agent fees           |     | $     | 0.20 |     | $                      | 0.199 |     | $     |   383,862.72 |
| Proceeds before expenses to us |     | $     | 2.30 |     | $                      | 2.294 |     | $     | 4,414,421.31 |

We have
agreed to pay the Placement Agent a total cash fee equal to 8.0% of the gross proceeds of this offering. We will also reimburse the Placement
Agent’s legal fees and expenses in an amount up to $120,000.

| 27 |

We estimate the total expenses of this offering paid or payable by us, exclusive of the Placement Agent’s cash fee and expenses payable by us, will be approximately $181,000. After deducting the fees and expenses due to the Placement Agent and our estimated expenses in connection with this offering, assuming we sell all of the shares and accompanying warrants offered hereby, we expect the net proceeds from this offering will be approximately $4.1 million.

Right of First Refusal

We have not granted the Placement Agent a right of first refusal following the closing of this offering to act as our sole book-running manager, sole manager, sole placement agent or sole agent for any further debt financing or refinancing or capital-raising transactions undertaken by us.

Tail

We have also agreed to pay the Placement Agent a tail fee equal to the cash and warrant compensation in this offering, if any investor,